Amneal Ruling: A Bright-Line Test for Device Patents Before December 20, 2024, branded drug manufacturers could argue that device patents covering components of a drug-device combination product qualified as drug product patents and thus belonged in the Orange Book
Key details Compounded GLP-1s Semaglutide injections Tirzepatide injections Semaglutide sublingual tablets Tirzepatide OTD Microdose options Liraglutide injections Branded GLP-1s Ozempic Mounjao Wegovy Mounjaro Foundayo (orforglipron) Brand-name medications carry a separate $25/month treatment plan fee on top of the medication cost
Scientists have identified variants in the gene coding for the enzyme PAM (peptidyl-glycine alpha-amidating monooxygenase) that appears to cause GLP-1 resistance
#weightloss #pharma #biospace To view or add a comment, sign in AnaptysBio Inc
Hydration also affects how the kidneys handle the glucose and metabolites the medication mobilizes, which matters for renal function
For a platform selling compounded GLP-1s, this is a gap worth noting
